CIBC Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

CIBC Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.4K	Sell	13,102 -26,418	-67%	-$51.5K	﹤0.01%	1416
2026 Q1	$61.7K	Hold	39,520	–	–	﹤0.01%	1339
2025 Q4	$45.4K	Buy	+39,520	New	+$54.3K	﹤0.01%	1350
2015 Q2	–	Sell	-3,433	Closed	-$23K	–	991
2015 Q1	$23K	Buy	3,433 +1,138	+50%	+$7.77K	﹤0.01%	962
2014 Q4	$15K	Sell	2,295 -308	-12%	-$2.48K	﹤0.01%	941
2014 Q3	$26K	Hold	2,603	–	–	﹤0.01%	972
2014 Q2	$29K	Hold	2,603	–	–	﹤0.01%	790
2014 Q1	$32K	Buy	+2,603	New	+$33.3K	﹤0.01%	1002

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

CIBC Asset Management's LXRX Position: Q2 2026 in Review

CIBC Asset Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 67% in Q2 2026, selling an estimated $51.5K and leaving 13,102 shares worth $31.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

CIBC Asset Management first reported a position in LXRX in Q1 2014 and has held it in 8 quarters since. The position peaked at $61.7K in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

CIBC Asset Management held 13,102 shares of Lexicon Pharmaceuticals worth $31.4K as of Q2 2026.
CIBC Asset Management sold 26,418 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $51.5K.
Lexicon Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1416 holding.
CIBC Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2014 and has held it in 8 quarters since.
CIBC Asset Management's Lexicon Pharmaceuticals position peaked at $61.7K in Q1 2026.
149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.